RTT News (09.20.12)
Aids Weekly Plus
The French pharmaceutical company, Sanofi, recently announced an agreement with the Global Alliance for TB Drug Development (TB Alliance) to collaborate on the discovery and development of new TB drugs. Both companies will work to develop novel compounds in Sanofi’s library that have shown promise against the TB bacterium. The agreement includes in-depth research of lead compounds based upon identified chemical derivatives of natural products and chemical optimization of other series of compounds that have been identified as hits in high-throughput screening. Sanofi discovered rifampicin, one of the first-line antituberculosis drugs, in the early 1960s.